Dr. Marie-Helene
Saint-Hilaire
Department of Neurology
Boston
University Medical Center, USA
Email: neuromsh@bu.edu
Qualifications
1987-1988 Fellowship in Parkinson’s Disease, Boston University School of
Medicine
1986-1987 Fellowship in extra-pyramidal disorders, Columbia Presbyterian Hospital
1985 EEG Fellowship, Notre Dame Hospital, Montreal
1984-1985 EEG
Fellowship, Montreal Neurological Institute
1981-1984 Residency in Neurology, Montreal Neurological Institute
1980-1981 Residency in Internal Medicine, Hôpital Saint-Luc, Montreal
1980 M.D., University of Montreal
1975 B.A.,
Biology and Biochemistry, College Marie de France, Montreal
Publications (selected)
-
Hohler AD, Tsao JM, Katz DI,
Dipiero TJ, Hehl CL, Leonard A, Allen V, Gardner M, Phenix H,
Saint-Hilaire M, Ellis T. Effectiveness of an Inpatient Movement Disorders Program
for Patients with Atypical parkinsonism.Parkinson’s Disease.
2012; 2012:871974. Epub 2011 Nov 10. PMID: 22135763.
-
J. -M. Lee, E. M. Ramos,J.-H. Lee,
T. Gillis,J.S. Mysore, M. R. Hayden, S. C. Warby, P. Morrison,
M. Nance, C.A. Ross, R.L. Margolis, F. Squitieri, S. Orobello, S. Di
Donato, E. Gomez-Tortosa, C. Ayuso, O. Suchowersky, R. J. A. Trent, E.
McCusker, A. Novelletto, M. Frontali, R. Jones, T. Ashizawa, S. Frank,
M. H. Saint-Hilaire, S. M. Hersch, H. D. Rosas, D. Lucente, M. B. Harrison, A.
Zanko, R. K. Abramson, K. Marder, J. Sequeiros, J. S. Paulsen, G. B.
Landwehrmeyer, R. H. Myers, M. E. MacDonald, and J. F. Gusella. CAG repeat
expansion in Huntington disease determines age at onset in a fully
dominant fashion Neurology March 6, 2012, 78: 690-695.
-
Hohler AD, Amariei DE, Katz DI,
DePiero TJ, Allen VB, Boyle S,
Phenix HA, De Angelis TA, Geibel CD, Smith KM, Saint-Hilaire MH,
Ellis T. Treating Orthostatic Hypotension in Patients with Parkinson’s
Disease and Atypical Parkinsonism
Improves Function.Journal of
Parkinson’s Disease. August 22, 2012. 10.3233/JPD-2012-012101.
-
Ramos EM, Latourelle JC, Lee
JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR,
Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C,
Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R,
Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D,
Harrison MB, Zanko A, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J,
Myers RH, Macdonald ME. Population stratification may bias analysis of
PGC-1α as a modifier of age at Huntington disease motor onset.Hum
Genet. 2012 , 131(12): 1833-40.
-
Ji-Hyun Lee, Jong-Min Lee,
Eliana Marisa Ramos, Tammy Gillis, Jayalakshmi S.Mysore, Shotaro
Kishikawa, Tiffany Hadzi, Audrey E. Hendricks, Michael R. Hayden, Patrick
J. Morrison, Martha Nance, Christopher A. Ross, Russell L. Margolis,
Ferdinando Squitieri, Cinzia Gellera, Estrella Gomez-Tortosa, Carmen
Ayuso, Oksana, Suchowersky, Ronald J. Trent, Elizabeth McCusker, Andrea
Novelletto, Marina Frontali, Randi Jones, Tetsuo Ashizawa, Samuel Frank,
Marie-Helene Saint-Hilaire, Steven M. Hersch, Herminia D. Rosas, Diane
Lucente, Madaline B. Harrison, Andrea Zankoa, Ruth K. Abramson, Karen
Marder, Jorge Sequeiros, G. Bernhard Landwehrmeyer on behalf of the Registry
Study of the European Huntington's Disease Network, Ira Shoulson on behalf
of the Huntington Study Group COHORT project, Richard H. Myers, Marcy E.
MacDonald, James F. Gusella. TAA repeat variation in the GRIK2 gene does
not influence age at onset in Huntington’s disease,Biochemical and
Biophysical Research Communications. 2012, 424404-408.
-
Zhang R, Spengler DC,
Saint-Hilaire MH, Hohler AD. Association of adverse effects with Monoamine
Oxidase type B Inhibitor and Catechol-O- Methyl Transferase Inhibitor
Combination Therapy In Parkinson’s Disease Patients.Advances in
Parkinson’s Disease. 1:5-10,2012.
-
Roy S, Cole B, Gilmore D, De
Luca C, Thomas C, Saint-Hilaire M, Syed N. High Resolution Tracking of
Motor Disorders In Parkinson’s Disease during Unconstrained Activity. Mov. Disord 2013,28:1080-1087.doi:10.1002/mds.25391.
-
Ramos EM, Latourelle JC, Gillis
T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR,
Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C,
Suchowersky O, Trent RJ, Mc Cusker E, Novelletto A, Frontali M, Jones R,
Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D,
Harrison MB, Zanko A, Abramson RK, Marder K, Gusella JF, Lee JM, Alonso I,
Sequeiros J, Myers RH, Macdonald ME. Candidate Glutamatergic and
Dopaminergic Pathway Gene Variants do not influence Huntington’s Disease
Motor Onset. Neurogenetics. 2013, 14:173-179 doi:
10.1007/s10048-013-0364-y.
-
Ellis T, Latham NK, De Angelis
TR, Thomas CA, Saint-Hilaire M, Bickmore T. Feasibility of a Virtual
Exercise Coach to Promote Walking in Community-Dwelling Persons with
Parkinson Disease.American Journal of Physical Medicine &
Rehabilitation. June 2013-Vol 92(6): 472-485.
-
Saint-Hilaire M, Ellis T. A
Prescription for Physical Therapy and Exercise.Advances in Parkinson Disease 2013, 2:118-120
doi:10.4236/apd.2013.24023.
-
Saint-Hilaire M. Occupational
therapy for Parkinson's disease: increasing awareness.Lancet Neurol. 2014 Jun; 13(6):527-9. PMID: 2472606.
-
Tickle-Degnen L, Saint-Hilaire
M, Thomas CA, Habermann B, Sprague
Martinez LS, Terrin N, Noubary F,
Naumova EN. Emergence and evolution of social self-management of
Parkinson¿s disease: study protocol for a 3-year prospective cohort study.BMC Neurology, May 2014, 14:95 doi: 10.1186/1471-2377-14-95.
-
Stacy M, Silver D, Mendis T,
Sutton J, Mori A, Chaikin P, Sussman NM, (Site Investigator). A 12-Week,
Placebo-Controlled Study (6002-US-006) of Istradefylline in Parkinson
Disease.Neurology, 2008; 70: 2233-2240.
-
Chirieac MC, Shinaman A,
Shoulson I and The Huntington Study Group COHORT Investigators. COHORT: A snapshot of Baseline
Characterisitcs. Neurotherapeutics 2008: 5(2): 365.
-
Kayson EP and the Huntington
Study Group PHAROS Investigators. Five years of Monitoring the Safety and
Feasibility of PHAROS (Prospective Huntington At Risk Observational
Study).Neurotherapeutics 2008; 5(2): 366.
-
Oster E, Dorsey ER, Bausch J,
Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington
Study Group PHAROS Investigators. Influence of Insurance on the Decision
to Pursue genetic Testing in Individuals at Risk for Huntington Disease. Neurotherapeutics 2008; 5(2): 368.
-
Quaid K, Sims S, Swenson M,
Harrison J, Moskowitz C, Stepanov N, Suter G, Westphal B, and the
Huntington Study Group PHAROS Investigators. Living at Risk: Concealing
Risk and Preserving Hope in Huntington Disease. Neurotherapeutics 2008; 5(2): 368-369.
-
Ravina B, Tanner C, DiEuliis D,
Eberly S, Flagg E, Galpern W, Fahn S, Goetz C, Grate S, Kurlan R, Lang A, Marek K, Kieburtz K,
Oakes D, Elliot R, Shoulson I, and the Parkinson Study Group LABS-PD
Investigators. A Longitudinal Program for Biomarker Development In
Parkinson’s Disease: A Feasibility Study. Movement Disorders, Vol 24, No. 14, 2009:
2081-2090.
-
Karen
Marder MD MPH, Hongwei Zhao PhD, Croline M. Tanner MD PhD, David Oakes PhD Ira
Shoulson MD and the Huntington Study Group PHAROS Investigators. Assessment of
dietary intake
among adults at risk for Huntington disease: Analysis of PHAROS research
participants.Neurology,2009, vol 73, No 5: 385-392.
-
Gross
RE, Watts RL, Hauser RA, Bakay RAE, Reichmann H, von Kummer R, Ondo WG,
Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W,
Cornfeldt M, Beebe K, Sandbrink R, and the Spheramine Investigational
Group. Intrastriatal transplantation of microcarrier-bound human retinal
pigment epithelial cells versus sham surgery in patients with advanced
Parkinson’s disease: a double –blind, randomised, controlled trial.Lancet
Neurology, 2011, Vol 10, No 6: 509-519.
-
Quaid
K, Swenson M, Sims S, Harrison J , Moskowitz C, Stepanov N, Suter GW, Westphal BJ for the Huntington Study Group
Investigators and Coordinators. What were you thinking? Individuals at
risk for Huntington disease Talk about Having children. Neurotherapeutics 2011: Vol 8 (1): 136-7.
-
Latourelle
JC, Hendricks AE, Pankratz N, Wilk JB, Halter C, Nichols WC, Gusella JF,
Destefano AL, Myers RH, Foroud T, and the PSG-Progeni GenePD Investigators, Coordinators, and
Molecular Genetic Laboratories. Genomewide linkage Study of Modifiers of
LRRK2-Related Parkinson’s Disease.Movement Disorders, 2011, vol 26, No 11:
2039-44.
-
Pankratz
N, Dumitriu
A, Hetrick
KN, Sun
M, Latourelle
JC, Wilk
JB, Halter
C, Doheny
KF, Gusella
JF, Nichols
WC, Myers
RH, Foroud
T, DeStefano
AL; PSG-PROGENI
and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number
variation in familial Parkinson disease. PLoS, 6(8): e20988. Epub,
2011.
-
Parkinson
Study Group. Phase II Safety, Tolerability, and Dose Selection Study of
Isradipine as a Potential Disease-Modifying Intervention in Early
Parkinson’Disease (STEADY-PD). Movement Disorders 2013, vol 28, No
13: 1823-1831, DOI: 10.1002/mds.25639.
-
The Parkinson
Study Group SURE-PD Investigators. Inosine to Increase Serum and
Cerebrospinal Fluid Urate in Parkinson Disease. JAMA Neurol. doi:10.1001/jamaneurol.2013.5528.
Profile Details
http://www.bumc.bu.edu/neurology/clinicalfaculty/hilaire/
Last Updated: 2014-09-26